Selinexor plus ICE chemo for brain-involved B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial tests a new drug, selinexor, combined with standard ICE chemotherapy for patients whose B-cell non-Hodgkin lymphoma has spread to the brain or spinal cord. It aims to see if adding selinexor improves treatment results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B-cell non-Hodgkin lymphoma that has spread to the brain or spinal cord.
- You have had at least one round of standard chemotherapy with a drug called anthracycline.
- You are 18 years old or older.
- You have at least one tumor that is 1.5 cm or larger that can be measured on scans.
- You are in fairly good health (ECOG score 0–2, meaning you can do most daily activities).
- Your blood counts and kidney/liver function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests selinexor given together with methotrexate and rituximab to treat lymphoma that has returned or not responded in the brain. It may help by attacking cancer cells in the central nervous system (brain/spinal fluid) after prior treatment.
This Phase 2 trial studies selinexor added to standard R-CHOP chemotherapy in people with a high-risk type of diffuse large B-cell lymphoma (DLBCL) that is “germinal center B-cell” (GC). It aims to improve disease control in people who need stronger treatment at the start.
This trial tests a combination of three drugs (selinexor, high-dose methotrexate, and rituximab) plus radiation for people with newly diagnosed central nervous system (CNS) lymphoma who cannot have a stem cell transplant. The goal is to see if this treatment can help control the cancer.
This trial tests a new combination of drugs (selinexor, temozolomide, and an immunotherapy) for people whose primary central nervous system lymphoma has come back or stopped responding to previous treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a combination of drugs (Orelabrutinib and Selinexor) with either Methotrexate, Thiotepa, or Temozolomide for people whose brain lymphoma has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
This trial tests a new combination: selinexor (a pill that targets cancer cells) plus a standard chemotherapy regimen (R-GDP) for people with relapsed or refractory DLBCL that has a specific genetic change in the TP53 gene. The goal is to see if this combination can help when other treatments have stopped working.
Hear when a new B-cell Lymphoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.